Achiko AG Announces Corporate Update Webcast

Commercial Delivery of its Saliva-Based Covid-19 Test AptameX™ Has Commenced

ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first, announced today that it will hold a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 9:00 am EST / 3:00 pm CET. A PowerPoint presentation will be available at the time of the call and published on the company website at

Details of webcast are as follows:

Date: Tuesday, November 22, 2022
Time: 9:00 am EST / 3:00 pm CET
Format: Zoom Call
Presenter: Mr. Steven Goh, CEO of Achiko AG
Meeting link: 
Meeting ID: 984 0412 3755
Passcode: achiko

Find your local number:

Recently, Achiko announced that it is commencing commercial deliveries of its Generation 2 AptameX™ Covid-19 test kit to Nahdlatul Ulama and other commercial clients, both starting in and around Jakarta. Nahdlatul Ulama is the Jakarta branch of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 schools and universities, and several hundred hospitals and clinics.

AptameX is the Company’s proprietary saliva-based Covid-19 test utilizing DNA aptamers bound to gold nanoparticles in a colloidal solution. The result is read by a UV Spectrophotometer and then analyzed with custom software. Unlike a molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests.

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.

The AptameX™ DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.

Media contacts:

Investor Relations

Switzerland & Global
Farner Consulting Ltd.
T: +41 44 266 67 67


This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.